Table 1 Baseline characteristics and incidence of clinical amenorrhea

Age, years

41.6 ± 4.4

42.1 ± 4.3

39.0 ± 4.1

Height, cm

154.8 ± 9.9

155.2 ± 10.3

152.4 ± 7.2

Weight, kg

61.0 ± 10.3

61.0 ± 10.2

60.9 ± 10.9

BMI¹, kg/m²

25.5 ± 3.2

25.3 ± 3.3

26.1 ± 3.0

Duration of symptoms months

29.1 ± 39.0

31.3 ± 41.7

17.2 ± 15.7

Age at menarche

13.0 [13.0;14.0]

13.0 [13.0;14.0]

13.5 [13.0;14.0]

Regular cycles:

regular cycles

69 (90.8%)

58 (90.6%)

11 (91.7%)

not

7 (9.21%)

6 (9.38%)

1 (8.33%)

Nulliparous:

no

74 (97.4%)

63 (98.4%)

11 (91.7%)

nulliparous

2 (2.63%)

1 (1.56%)

1 (8.33%)

Breastfed:

breastfed

73 (96.1%)

61 (95.3%)

12 (100%)

no

3 (3.95%)

3 (4.69%)

0 (0.00%)

Socioeconomic status:

Low

42 (55.3%)

37 (57.8%)

5 (41.7%)

High

34 (44.7%)

27 (42.2%)

7 (58.3%)

Hypertension:

Hypertensive

2 (2.63%)

2 (3.12%)

0 (0.00%)

not

74 (97.4%)

62 (96.9%)

12 (100%)

Diabetic:

diabetic

3 (3.95%)

3 (4.69%)

0 (0.00%)

no

73 (96.1%)

61 (95.3%)

12 (100%)

T: Status

T1

10 (13.2%)

8 (12.5%)

2 (16.7%)

T2

41 (53.9%)

35 (54.7%)

6 (50.0%)

T3

17 (22.4%)

13 (20.3%)

4 (33.3%)

T4

8 (10.5%)

8 (12.5%)

0 (0.00%)

N: Status

N0

29 (38.2%)

22 (34.4%)

7 (58.3%)

N1

26 (34.2%)

22 (34.4%)

4 (33.3%)

N2

14 (18.4%)

13 (20.3%)

1 (8.33%)

N3

7 (9.21%)

7 (10.9%)

0 (0.00%)

M: M0

76 (100%)

64 (100%)

12 (100%)

stage:

stage IA

5 (6.58%)

4 (6.25%)

1 (8.33%)

stage IIA

21 (27.6%)

16 (25.0%)

5 (41.7%)

stage IIB

18 (23.7%)

15 (23.4%)

3 (25.0%)

stage III A

19 (25.0%)

16 (25.0%)

3 (25.0%)

stage III B

6 (7.89%)

6 (9.38%)

0 (0.00%)

stage III C

7 (9.21%)

7 (10.9%)

0 (0.00%)

Histopathology:

mixed

1 (1.32%)

1 (1.56%)

0 (0.00%)

pure

75 (98.7%)

63 (98.4%)

12 (100%)

Grade:

grade 1

5 (6.67%)

5 (7.94%)

0 (0.00%)

2

39 (52.0%)

34 (54.0%)

5 (41.7%)

3

31 (41.3%)

24 (38.1%)

7 (58.3%)

ER²

ER + ve

35 (46.1%)

31 (48.4%)

4 (33.3%)

-ve

41 (53.9%)

33 (51.6%)

8 (66.7%)

PR³

PR + ve

22 (28.9%)

20 (31.2%)

2 (16.7%)

-ve

54 (71.1%)

44 (68.8%)

10 (83.3%)

Chemo regimen:

AC⁴ > docetaxel

52 (68.4%)

43 (67.2%)

9 (75.0%)

AC > paclitaxel

20 (26.3%)

18 (28.1%)

2 (16.7%)

TAC⁵

4 (5.26%)

3 (4.69%)

1 (8.33%)

Hormonal treatment:

No

39 (52.7%)

32 (50.8%)

7 (63.6%)

Yes

35 (47.3%)

31 (49.2%)

4 (36.4%)

Tamoxifen

35 (100%)

31 (100%)

4 (100%)